source
- Pharma leaders turn to integrated scenario modeling as US MFN pricing reshapes global launch strategiesThe article explains that integrated scenario modeling is becoming a key tool for pharmaceutical executives facing pricing uncertainty and the complexities of worldwide product launches. It refere…
- Top pharma firms line up for Summit Therapeutics' ivonescimab after strong China Phase 3 dataSeveral major biopharma companies, including AstraZeneca, Pfizer and Revolution Medicines, are expressing strong interest in Summit Therapeutics' Akeso-partnered bispecific antibody ivonescimab. Th…